Because of the heterogeneity of acquired mutations, leading to the presence of the multiple alterations in one patient or even in one organ/one metastatic lesion [5], more specific KIT inhibitors have only a limited effectiveness in highly resistant GIST. Here, KIT is linked to gastrointestinal stromal tumor.